FIGURE 2.

BI treatment persistence for each insulin type in T2D naïve users (A); from first observed switch in T2D prevalent users (B); from first observed switch in T1D prevalent users (C). Insulin purchase gap of 7 months. The follow‐up time for degludec and Gla‐300 was limited, and median persistence thus not reached in all settings. p < .0001 denotes significant differences between median persistence with medications reaching a median value obtained using the log‐rank test. Gla, glargine; T1D, type 1 diabetes; T2D, type 2 diabetes.